Irkutsk anti-plague institute death prompts quarantines and conflicting official accounts.
|Videos|May 29, 2020
Contagion Live News Network: More Hydroxychloroquine Concerns
Author(s)Grant M. Gallagher
A daily infectious disease news update
Advertisement
Hello and thank you for joining Contagion. I’m here with a brief on our latest infectious disease clinical coverage:
A study team supported by the Agency for Healthcare Research and Quality, sought to summarize evidence about the benefits and harms of hydroxychloroquine and chloroquine as treatments or prophylaxis of COVID-19. The study team ultimately concluded that evidence on the benefits and harms of using hydroxychloroquine or chloroquine to treat COVID-19 is very weak and conflicting, alongside a lack of empirical study on use as prophylaxis.
In other news, early links between heart disease and diabetes with coronavirus severity caused some to fear that ACE inhibitors and ARBs might worsen outcomes during the pandemic. A systematic review finds little evidence to back those fears.
And lastly, in an interview with our editorial director, Dr. Kelly Cawcutt, shared her thoughts on COVID's impact on health care, as well as why it's so important for clinicians to take breaks.
For more on these stories and the latest infectious disease news, visit contagionlive.com. Thanks for watching.
Advertisement
Related to this article
A laboratory technician at a Siberian anti-plague institute has died of pneumonia of unknown cause, prompting quarantines and contact monitoring while Russian officials stop short of confirming plague.
A study finding clesrovimab comparable to palivizumab in protecting at-risk infants in their first RSV season was extended to demonstrate clesrovimab effective and well-tolerated when administered in their second season.
Lori Handy, MD, provides guidance in these areas including presentation before rash onset, when patients should be considered for the inpatient setting, and what treatment looks like.
Jason Pogue, PharmD, BCPS, BCIDP, contextualizes preliminary data looking at this trial and other extended-spectrum beta-lactamase (ESBL) studies, which reopens the debate around carbapenem-sparing treatment options.
In the phase 3 LIBERTY study, the investigational monoclonal antibody, VYD2311, had significantly fewer adverse events than an mRNA COVID-19 vaccine, and it did not blunt vaccine-induced neutralizing titers when the two were given together.
With a significant increase in rabies exposures this year, Rodney Rohde, PhD, talks about seeking medical attention after animal interactions as well as clinical treatment when people have been bit or scratched.
In the first episode of our new series looking at the food safety network, Lynette Johnston, PhD, offers insights into how the federal government surveillance infrastructure operates and how epidemiologists serve as food detectives in determining bacterial pathogens and potential foodborne outbreaks.
Advertisement
Advertisement